.Pharmacolibrary.Drugs.ATC.L.L04AF05 .Pharmacolibrary.Drugs.ATC.L.L04AF05| name: | Itacitinib |
| ATC code: | L04AF05 | route: | oral |
| n-compartments | 2 |
Itacitinib is an oral, selective inhibitor of Janus kinase 1 (JAK1) developed for the treatment of graft-versus-host disease (GVHD) and hematological malignancies. While itacitinib has undergone several clinical trials, it is not currently FDA-approved for any indication as of 2024.
Pharmacokinetic parameters reported for adult patients with hematological malignancies and healthy volunteers. Data reflect single and multiple oral doses in clinical studies.
Covington, M, et al., & Smith, P (2020). Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases. European journal of pharmacology 885 173505–None. DOI:10.1016/j.ejphar.2020.173505 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32861662